Cargando…

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam

Dissemination of prostate-specific antigen (PSA) testing in the United States coincided with an increasing incidence of prostate cancer, a shift to earlier stage disease at diagnosis, and decreasing prostate cancer mortality. We compared PSA screening performance with respect to prostate cancer dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wever, Elisabeth M., Draisma, Gerrit, Heijnsdijk, Eveline A. M., Roobol, Monique J., Boer, Rob, Otto, Suzie J., de Koning, Harry J.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831048/ https://www.ncbi.nlm.nih.gov/pubmed/20142584 http://dx.doi.org/10.1093/jnci/djp533

Ejemplares similares

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
por: Wever, E M, et al.
Publicado: (2012)

Interpreting Overdiagnosis Estimates in Population-based Mammography Screening
por: de Gelder, Rianne, et al.
Publicado: (2011)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
por: Hogenhout, Renée, et al.
Publicado: (2022)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
por: Remmers, Sebastiaan, et al.
Publicado: (2023)

Cost‐effectiveness of multiparametric magnetic resonance imaging and MRI‐guided biopsy in a population‐based prostate cancer screening setting using a micro‐simulation model
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
por: Pereira-Azevedo, Nuno, et al.
Publicado: (2017)

Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths
por: de Gelder, R, et al.
Publicado: (2011)

Prostate cancer screening and active surveillance in the Western world
por: Roobol, Monique J.
Publicado: (2018)

Personalized strategies in population screening for prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2020)

Prostate cancer screening in Europe and Asia
por: Zhang, Kai, et al.
Publicado: (2017)

Ethnicity and prostate cancer: the way to solve the screening problem?
por: Bokhorst, Leonard P., et al.
Publicado: (2015)

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals
por: van Ravesteyn, N T, et al.
Publicado: (2011)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening
por: Draisma, Gerrit, et al.
Publicado: (2013)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator
por: de Vos, Ivo I., et al.
Publicado: (2023)

Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
por: Zielonke, Nadine, et al.
Publicado: (2021)

Screening for cancers with a good prognosis: The case of testicular germ cell cancer
por: Heijnsdijk, Eveline A. M., et al.
Publicado: (2021)

Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data
por: de Koning, Harry J, et al.
Publicado: (2006)

The cost-effectiveness of different visual acuity screening strategies in three European countries: A microsimulation study
por: Heijnsdijk, Eveline A.M., et al.
Publicado: (2022)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas
por: Heijnsdijk, Eveline A. M., et al.
Publicado: (2022)

Editorial Comment: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
por: Hugosson, J, et al.
Publicado: (2020)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modelled strategies
por: Kregting, Lindy M., et al.
Publicado: (2022)

Overcoming barriers: Modelling the effect of potential future changes of organized breast cancer screening in Italy
por: Zielonke, Nadine, et al.
Publicado: (2023)

Reply to: Comments on “Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modeled strategies”
por: Kregting, Lindy M., et al.
Publicado: (2022)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk
por: Geuzinge, H. Amarens, et al.
Publicado: (2021)

Predicting biochemical recurrence and prostate cancer‐specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening‐ and clinically detected prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2019)

Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform †
por: Beyer, Katharina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_29845b1iovpcas68hhh92e7985